Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone

Am J Obstet Gynecol. 1996 May;174(5):1584-9. doi: 10.1016/s0002-9378(96)70610-5.


Objective: The purpose of this study was to compare the use of low-dose aspirin alone with heparin and low-dose aspirin in the treatment of the antiphospholipid antibody syndrome.

Study design: A prospective, single-center trial included 50 patients who were alternately assigned to treatment. Each patient had at least three consecutive spontaneous pregnancy losses, positive antiphospholipid antibodies on two occasions, and a complete evaluation. Data were compared by chi(2) analysis and Fisher's exact test.

Results: Viable infants were delivered of 11 of 25 (44%) women treated with aspirin and 20 of 25 (80%) women treated with heparin and aspirin (p < 0.05). There were no significant differences between the low-dose aspirin and the heparin plus low-dose aspirin groups with respect to gestational age at delivery (37.8 +/- 2.1 vs 37.2 +/- 3.4 weeks), number of cesarean sections (18% vs 20%), or complications.

Conclusion: Heparin plus low-dose aspirin provides a significantly better pregnancy outcome than low-dose aspirin alone does for antiphospholipid antibody-associated recurrent pregnancy loss.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Abortion, Habitual / drug therapy*
  • Abortion, Habitual / etiology
  • Abortion, Habitual / immunology*
  • Adult
  • Antiphospholipid Syndrome / complications
  • Antiphospholipid Syndrome / drug therapy*
  • Antiphospholipid Syndrome / immunology*
  • Aspirin / administration & dosage*
  • Aspirin / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Heparin / therapeutic use*
  • Humans
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Pregnancy Complications / immunology*
  • Pregnancy Outcome
  • Prospective Studies


  • Heparin
  • Aspirin